| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(06)69829-2 |
| P50 | author | Salim Yusuf | Q2214381 |
| Hertzel C. Gerstein | Q41696958 | ||
| P2093 | author name string | Jackie Bosch | |
| P433 | issue | 9552 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2050-2051 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | The DREAM trial – Authors' reply | |
| P478 | volume | 368 |
| Q36973815 | A cardiologist view of vascular disease in diabetes |
| Q37076275 | Acarbose: oral anti-diabetes drug with additional cardiovascular benefits |
| Q33488336 | Actos Now for the prevention of diabetes (ACT NOW) study |
| Q38264613 | Biology of upper-body and lower-body adipose tissue--link to whole-body phenotypes. |
| Q51366399 | Biomarkers in Type 2 diabetes: improving risk stratification with the PreDx ® Diabetes Risk Score. |
| Q38003648 | Buccal spray insulin (Oralgen) for type 2 diabetes: what evidence? |
| Q38205374 | Cardiovascular risk stratification and management in pre-diabetes |
| Q44175885 | Clinical research of traditional Chinese medical intervention on impaired glucose tolerance |
| Q36624990 | Comparative safety of newer oral antidiabetic drugs |
| Q46569270 | Confusion over thiazolidinedione-induced heart failure: need for a better definition of heart failure |
| Q36955489 | Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials |
| Q51466229 | Diagnosing abnormal glucose tolerance in hypertensive women: are we making the best choice? |
| Q36822448 | Drug discovery in the metabolic syndrome: context and some recent developments |
| Q37118473 | Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal |
| Q36424107 | Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial |
| Q26767164 | Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials |
| Q37045165 | Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes |
| Q51822110 | Early management of type 2 diabetes based on a SMBG strategy: the way to diabetes regression--the St Carlos study : a 3-year, prospective, randomized, clinic-based, interventional study with parallel groups. |
| Q46794502 | Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients. |
| Q36866334 | Fat targets for skeletal health |
| Q35505266 | Gestational diabetes mellitus: risks and management during and after pregnancy. |
| Q37000780 | Glitazones in the treatment of cardiovascular risk factors |
| Q35757053 | Higher glucose, insulin and insulin resistance (HOMA-IR) in childhood predict adverse cardiovascular risk in early adulthood: the Pune Children's Study |
| Q36966063 | Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. |
| Q26830871 | Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes |
| Q81415867 | Is rosiglitazone associated with increased risk for cardiovascular events? |
| Q37012012 | Measuring biomarkers to assess the therapeutic effects of PPAR agonists? |
| Q36868655 | Metabolic syndrome and cardiovascular disease: challenges and opportunities |
| Q38189473 | Metabolic syndrome and polycystic ovary syndrome: an intriguing overlapping. |
| Q45265388 | Metabolic syndrome and the older male population |
| Q29615359 | Metabolite profiles and the risk of developing diabetes |
| Q38645269 | Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study |
| Q36847318 | Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes |
| Q38971792 | New fixed dose chemical combinations: the way forward for better diabetes type II management? |
| Q51605998 | New therapeutic algorithm of Type 2 diabetes: lights and shadows. |
| Q37943863 | Peroxisome proliferator-activated receptor-γ and the endothelium: implications in cardiovascular disease |
| Q35636191 | Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease |
| Q37016305 | Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease |
| Q43151782 | Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome |
| Q36918107 | Pharmacogenetics of thiazolidinedione therapy |
| Q46679104 | Pharmacogenomics of metabolic effects of rosiglitazone |
| Q36945108 | Pharmacological intervention in prediabetes: considering the risks and benefits |
| Q34781949 | Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials |
| Q37606430 | Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance |
| Q36909303 | Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects |
| Q37142044 | Pleiotropic effects of thiazolidinediones |
| Q44754092 | Predictors of lifestyle intervention outcome and dropout: the SLIM study |
| Q34123051 | Prevalence of diabetes among Han, Manchu and Korean ethnicities in the Mudanjiang area of China: a cross-sectional survey |
| Q45718512 | Prevention of Type 2 Diabetes with the Chinese Herbal Medicine Tianqi Capsule: A Systematic Review and Meta-Analysis |
| Q37013032 | Prevention of Type 2 diabetes: fact or fiction? |
| Q38236171 | Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis |
| Q36945100 | Reflecting on type 2 diabetes prevention: more questions than answers! |
| Q37566650 | Rosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound. |
| Q36945104 | Screening and diagnosis of prediabetes: where are we headed? |
| Q59193422 | Setting the record straight on TIDE: a lost opportunity for patients with diabetes |
| Q35480518 | Sex-specific differences in diabetes prevention: a systematic review and meta-analysis |
| Q38907817 | Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes? |
| Q34004470 | Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance |
| Q30250347 | The current role of thiazolidinediones in diabetes management |
| Q38537377 | The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis |
| Q35857634 | The efficacy and safety of probiotics intervention in preventing conversion of impaired glucose tolerance to diabetes: study protocol for a randomized, double-blinded, placebo controlled trial of the Probiotics Prevention Diabetes Programme (PPDP). |
| Q37299239 | The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety |
| Q30484253 | The prevention of type 2 diabetes |
| Q38016454 | The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review |
| Q36709546 | The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? |
| Q26822066 | Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention |
| Q37142138 | Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update |
| Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
| Q37835820 | Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. |
| Q36996294 | Thiazolidinediones as anti-inflammatory and anti-atherogenic agents |
| Q36815978 | Treating the metabolic syndrome. |
| Q58447602 | Type 2 diabetes mellitus |
| Q37069176 | Type 2 diabetes mellitus and heart failure. |
| Q58039484 | Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI |
| Q36947018 | beta-cell function and anti-diabetic pharmacotherapy |
Search more.